Literature DB >> 30246233

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.

D Bengtsson1, H D Schrøder2, K Berinder3, D Maiter4, C Hoybye3, O Ragnarsson5, U Feldt-Rasmussen6, Å Krogh Rasmussen6, A van der Lely7, M Petersson3, G Johannsson5, M Andersen8, P Burman9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30246233     DOI： 10.1007/s12020-018-1751-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  13 in total

Review 1.  DNA damage response.

Authors:  Giuseppina Giglia-Mari; Angelika Zotter; Wim Vermeulen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

2.  Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.

Authors:  Ann I McCormack; John A H Wass; Ashley B Grossman
Journal:  Eur J Clin Invest       Date:  2011-04-18       Impact factor: 4.686

3.  A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Authors:  Mineko Murakami; Akiko Mizutani; Shuichiro Asano; Hideki Katakami; Yoshinori Ozawa; Kazuto Yamazaki; Yasuo Ishida; Koji Takano; Hiroko Okinaga; Akira Matsuno
Journal:  Neurosurgery       Date:  2011-06       Impact factor: 4.654

4.  Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Authors:  Hélène Lasolle; Christine Cortet; Fréderic Castinetti; Lucie Cloix; Philippe Caron; Brigitte Delemer; Rachel Desailloud; Christel Jublanc; Christine Lebrun-Frenay; Jean-Louis Sadoul; Luc Taillandier; Marie Batisse-Lignier; Fabrice Bonnet; Nathalie Bourcigaux; Damien Bresson; Olivier Chabre; Philippe Chanson; Cyril Garcia; Magalie Haissaguerre; Yves Reznik; Sophie Borot; Chiara Villa; Alexandre Vasiljevic; Stephan Gaillard; Emmanuel Jouanneau; Guillaume Assié; Gérald Raverot
Journal:  Eur J Endocrinol       Date:  2017-06       Impact factor: 6.664

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.

Authors:  Davide Campana; Thomas Walter; Sara Pusceddu; Fabio Gelsomino; Emmanuelle Graillot; Natalie Prinzi; Andrea Spallanzani; Michelangelo Fiorentino; Marc Barritault; Filippo Dall'Olio; Nicole Brighi; Guido Biasco
Journal:  Endocrine       Date:  2017-11-17       Impact factor: 3.633

Review 7.  Aggressive pituitary tumours and carcinomas: two sides of the same coin?

Authors:  Jacqueline Trouillas; Pia Burman; Ann McCormack; Stephan Petersenn; Vera Popovic; Olaf Dekkers; Gerald Raverot
Journal:  Eur J Endocrinol       Date:  2018-03-27       Impact factor: 6.664

8.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

Authors:  Ann McCormack; Olaf M Dekkers; Stephan Petersenn; Vera Popovic; Jacqueline Trouillas; Gerald Raverot; Pia Burman
Journal:  Eur J Endocrinol       Date:  2018-01-12       Impact factor: 6.664

9.  Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.

Authors:  Dwight H Owen; Andrew J Alexander; Bhavana Konda; Lai Wei; Jessica A Hemminger; Carl R Schmidt; Sherif R Z Abdel-Misih; Mary E Dillhoff; Jennifer A Sipos; Lawrence S Kirschner; Manisha H Shah
Journal:  Oncotarget       Date:  2017-10-24

Review 10.  Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.

Authors:  Luis V Syro; Fabio Rotondo; Mauricio Camargo; Leon D Ortiz; Carlos A Serna; Kalman Kovacs
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-15       Impact factor: 5.555
View more
  4 in total

Review 1.  Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.

Authors:  Anli Tong; Ming Li; Yunying Cui; Xiaosen Ma; Huiping Wang; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-18       Impact factor: 5.555

Review 2.  Aggressive corticotroph tumors and carcinomas.

Authors:  Hélène Lasolle; Alexandre Vasiljevic; Emmanuel Jouanneau; Mirela Diana Ilie; Gérald Raverot
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

3.  Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis.

Authors:  Mei Luo; Yiheng Tan; Wenli Chen; Bin Hu; Zongming Wang; Diming Zhu; Haosen Jiao; Chengbin Duan; Yonghong Zhu; Haijun Wang
Journal:  Front Neurol       Date:  2021-06-18       Impact factor: 4.003

Review 4.  Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.

Authors:  Sam Ng; Mahmoud Messerer; Julien Engelhardt; Michaël Bruneau; Jan Frederick Cornelius; Luigi Maria Cavallo; Giulia Cossu; Sebastien Froelich; Torstein R Meling; Dimitrios Paraskevopoulos; Henry W S Schroeder; Marcos Tatagiba; Idoya Zazpe; Moncef Berhouma; Roy T Daniel; Edward R Laws; Engelbert Knosp; Michael Buchfelder; Henri Dufour; Stéphane Gaillard; Timothée Jacquesson; Emmanuel Jouanneau
Journal:  Acta Neurochir (Wien)       Date:  2021-08-08       Impact factor: 2.816
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.